JNJ
Johnson & Johnson
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) recei
·Consolidated from 2 sources
{ "headline": "J&J Seeks Talc Settlement, Sees Head and Neck Cancer Drug Advance", "summary": "Johnson & Johnson is pursuing a significant settlement
{ "headline": "J&J Seeks Talc Settlement, Sees Head and Neck Cancer Drug Advance", "summary": "Johnson & Johnson is pursuing a significant settlement
Sources
This recap was generated by consolidating the public headlines below.
- Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancerJul 30, 2026
- Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit SettlementJul 30, 2026